Filing Details
- Accession Number:
- 0000950170-24-027253
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-06 16:46:58
- Reporting Period:
- 2024-03-04
- Accepted Time:
- 2024-03-06 16:46:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1347178 | Vanda Pharmaceuticals Inc. | VNDA | Pharmaceutical Preparations (2834) | 030491827 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1806596 | Patrick Kevin Moran | 2200 Pennsylvania Avenue Nw Suite 300E Washington DC 20037 | Svp, Cfo & Treasurer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-03-04 | 5,798 | $4.48 | 239,916 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-05 | 8,902 | $4.20 | 231,014 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 635 | Indirect | By Wife |
Footnotes
- Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.435 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.195 to $4.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Billionaire Hedge Funds
